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Abstract
Background: Countries of the Americas have been working towards rubella elimination since 2003 and endemic
rubella virus transmission appears to have been interrupted since 2009. To contribute towards monitoring of rubella
elimination, we assessed rubella seroprevalence among prenatal screening tests performed in Ontario.
Methods: Specimens received for prenatal rubella serologic testing at the Public Health Ontario Laboratory, the
provincial reference laboratory, between 2006 and 2010 were analyzed. A patient-based dataset was created using
all tests occurring among 15–49 year-old females, where prenatal screening was indicated. Multiple tests were
assigned to the same patient on the basis of health card number, name and date of birth. Only unique tests
performed at least nine months apart were included. SAS version 9.2 was used for analysis.
Results: Between 2006 and 2010, we identified 459,963 women who underwent 551,160 unique prenatal screening
tests for rubella. Of these, 81.6%, 17.1% and 1.4% had one, two and three or more tests respectively.
Rubella immunity remained stable at approximately 90% overall; the proportion of susceptible women was 4.4%.
Additionally, 0.6% of women were initially susceptible and subsequently developed immunity. Across the province,
susceptibility was highest in the north and declined with increasing age (p < 0.0001). Among women with multiple
tests, the proportion who remained susceptible declined as the number of years between tests increased
(p < .0001). Based on age at first test, younger women had the highest susceptibility (4.2% among 15–19 year-olds)
and were significantly more likely to develop immunity if previously susceptible (p < .0001).
Conclusion: Rubella susceptibility among prenatal women in Ontario supports elimination goals as population
immunity in this group is relatively high. Higher susceptibility among young women and women living in the
north highlights an opportunity for greater focus on identification and immunization of susceptible women in
these groups.
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Background
Countries of the Americas have been working towards
the goal of eliminating rubella and congenital rubella
syndrome (CRS) since 2003 and endemic rubella virus
transmission appears to have been interrupted since
2009 [1,2]. With the guidance of a Plan of Action from
the Pan American Health Organization (PAHO), mem-
ber states are currently documenting and verifying inter-
ruption of endemic rubella virus transmission in their
respective jurisdictions [2]. The Plan of Action describes
six components which will provide support that measles
and/or rubella/CRS has been eliminated. This includes
high population immunity demonstrated by immuniza-
tion coverage estimates and supported by seroprevalence
studies where available.
In Canada, rubella immunization coverage goals were
set in 2005 to achieve and maintain 97% coverage for one
dose of rubella-containing vaccine among children by
their second birthday, and 97% coverage for two doses of
rubella-containing vaccine among 7 and 17-year olds by
2010 [3]. In Ontario, Canada’s largest province (population
13.7 million), rubella-containing vaccine has been admin-
istered as part of publicly funded immunization programs
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since 1970. Introduced in 1975, it has been administered
as part of a one-dose schedule of the combined measles,
mumps, rubella (MMR) vaccine. To improve measles con-
trol, a two-dose MMR program was introduced in 1996,
where the first dose was administered at 12 months and
the second dose was administered at 4–6 years until 2007,
where the second dose was administered at 18 months. As
of August 2011, the second dose is administered as a com-
bined measles, mumps, rubella and varicella (MMRV) vac-
cine among 4–6 year olds. A single dose of monovalent
measles vaccine was offered to all students aged 4–18 years
in 1996 as part of a measles catch-up campaign. In
Ontario, as legislated by the Immunization of School
Pupils Act, immunization with at least one dose of
rubella-containing vaccine is required for school attend-
ance, unless a valid medical exemption or statement of
religious or conscientious objection is provided.
One imported case of congenital rubella syndrome
and 12 confirmed cases of rubella were reported in
Ontario between 2006 and 2011; none of these cases
were determined to be endemic [4]. The last reported
case of rubella in Ontario occurred in January 2012 and
was assessed to be travel-related [5]. Immunization
coverage for at least one dose of rubella-containing vac-
cine was estimated to be 95.0% and 96.6% among children
7 and 17 years of age respectively during the 2010–11
school year [6]. Unfortunately, as Ontario does not have a
comprehensive immunization registry, coverage among
pre-school children or adults cannot be assessed. At the
national level, self-reported data obtained through tele-
phone surveys estimate one-dose coverage of MMR vac-
cine as 92% among 2 year olds in 2009 [7] and 71%
among adults < 38 years in 2008 (personal communica-
tion, S. Desai). National targets have been set to decrease
susceptibility among primigravida women to less than
4% and to achieve 99% coverage in susceptible women
postpartum [3].
Seroprevalence can provide additional evidence of
population immunity particularly among specific target
groups for immunization; because of primary and sec-
ondary vaccine failure, coverage only provides a proxy
for immunity. In Canada, it is recommended that all
pregnant women are screened to determine susceptibil-
ity to rubella and facilitate post-partum immunization of
susceptible women, increasing the feasibility of assessing
rubella seroprevalence [8,9]. A small number of Canadian
studies have assessed seroprevalence of rubella in selected
adult populations including military recruits, daycare
workers and newly arrived immigrants and refugees
[10-12] but only a few studies have specifically assessed
pregnant women [13-15].
The objectives of our study are to determine rubella
susceptibility in a sample of prenatal rubella screening
tests conducted in Ontario; to identify demographic
factors associated with non-immune rubella titres and
contribute towards monitoring of rubella elimination in
Ontario and Canada.
Methods
In Ontario, prenatal specimens as well as those for occu-
pational health pre-employment screening, are sent
to the provincial reference laboratory, Public Health
Ontario Laboratory (PHOL) for serologic testing. We
analyzed all prenatal specimens received for rubella
serology testing at the PHOL between January 1, 2006 and
December 31, 2010. In Ontario, although private and hos-
pital laboratories have the ability to perform rubella pre-
natal testing, virtually all such testing is performed at
PHOL at a dedicated prenatal laboratory. We extracted
data from two laboratory information systems: Labyrinth
(January 2006 - April 2010) and Labware (April 2010 -
December 2010) and merged specimen-based data ex-
tracts from both information systems. If more than one
test was performed on a single specimen, we used the re-
sult from the last test performed on the specimen.
For diagnostic samples, serologic testing for rubella
antibodies, both immunoglobulin G (IgG) and IgM, were
performed using the Enzygnost Rubella IgG and IgM en-
zyme immunoassays (EIA) on a BEP 2000 Analyzer
(Siemens AG, Germany) until March 2010. Thereafter,
the Euroimmun Anti-Rubella IgG and IgM enzyme-
linked immunosorbent assays (ELISA) were used on a
Euroimmun Analyzer I (Euroimmun AG, Luebeck,
Germany). Serum samples for prenatal screening of ru-
bella IgG antibodies were performed using the Abbott
Microparticle-Enzyme Immunoassay (MEIA) on an
Axsym (Abbott Diagnostics, Illinois, USA). All assays
were performed according to the respective manufac-
turers’ instructions. Immune status was determined
using the following cut-off values: < 5.0 IU/mL (Suscep-
tible), 5.0-9.9 IU/mL (Indeterminate), > = 10.0 IU/mL
(Immune).
We created a prenatal patient-based dataset by
selecting all tests where the reason for testing was speci-
fied as prenatal, the patient was female and was between
15 and 49 years of age. Multiple tests were assigned to
the same patient on the basis of health card number
(HCN), name and date of birth (DOB). First, records
with a valid HCN were assigned a unique patient identi-
fier and grouped accordingly; next, records that did not
have a valid HCN but whose name and DOB matched
that of the patients identified in the first round were
considered to belong to the same patient; third, among
the remaining unlinked records, multiple records were
assigned to the same patient on the basis of name and
DOB only; lastly, all remaining records that could not be
linked to previously identified patients were treated as
distinct patients.
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To eliminate multiple tests in the same patient that
were performed within a short time period and were
likely related to the same pregnancy, test results were
excluded if they were performed within nine months of
another test. Among patients who had multiple tests,
different results were summarized into broad categories
using the following approach: ‘Susceptible’, ‘Indetermin-
ate’ and ‘Immune’ status was assigned to patients for
whom all tests indicated a status of susceptible, inde-
terminate and immune status, respectively; ‘Immune-
Susceptible’ status was assigned to patients for whom
the initial and possibly subsequent tests indicated immun-
ity followed by and ending with test(s) that indicated sus-
ceptibility; ‘Susceptible-Immune’ status was assigned to
patients for whom the initial and possibly subsequent tests
indicated susceptibility followed by and ending with test(s)
that indicated immunity; ‘Other’ status was assigned to pa-
tients who had all other combinations of test results (e.g.
Immune- Susceptible-Immune-Indeterminate).
Variables that were available for analysis were limited
to information captured on the laboratory requisition
forms, and comprised of the patient’s date of birth, sex
and city of residence or postal code. The date of birth
and date on which the specimen was received at PHOL
were used to determine the age of the patient at the time
that the test was performed. Patient residence was deter-
mined using a combination of the reported city of resi-
dence (prior to April 2010) and postal code (after April
2010). In the event this information was unavailable, the
postal code of the requesting health care provider was
used instead. In Ontario, local health promotion and dis-
ease prevention programs are delivered by 36 public
health units which vary in size and demographic profile.
The corresponding health unit was determined using the
public health unit locator resource available through the
Ontario Ministry of Health and Long-Term Care (when
city was reported) and the 2009 Postal Code Conversion
File maintained by Statistics Canada (when postal code
was reported). Incidence rates were calculated using popu-
lation data from Statistics Canada. Annualized rates were
derived by dividing the numerator of interest by the com-
bined female population between 2006 and 2010.
SAS version 9.2 was used to compile and manipulate
all datasets. Descriptive analyses and statistical tests of
comparisons were also conducted within SAS. Statistical
tests to compare rates between age groups and health
regions were based on the binomial distribution. Com-
parisons over time were based on the Cochran-Armitage
test to test for trends over time. Statistical significance
was declared at p < 0.05.
Results
As depicted in Figure 1, we extracted 1,048,929 test re-
sults relating to rubella serology from the laboratory
information systems at PHOL between 2006 and 2010.
Of these, 600,859 prenatal tests were conducted among
459,963 female patients between 15 and 49 years of age.
The elimination of tests conducted less than nine
months apart for the same patient resulted in 551,160
unique prenatal testing episodes for analysis. Within this
cohort, 81.6% of women (N = 375,219) had one unique
prenatal test during the 5-year study period, while 17.1%
(N = 78,517) had two and 1.4% (N = 6,227) had three or
more prenatal tests at least nine months apart.
Over the study period, approximately 90% of the pre-
natal specimens demonstrated immunity to rubella, with
little variation over time (Figure 2). There was more
variation among susceptibility, ranging from 5.0% in
2007 to 3.9% in 2009. Across the province, susceptibility
was highest among pregnant women in the northern
health units during the study period (Figure 3). The pro-
portion of women who developed immunity in subse-
quent pregnancies after initially being susceptible to
rubella was also highest in the northern health region
(1.0%), while Toronto was associated with the lowest
proportion (0.4%).
Between 2006 and 2010, the overall proportion of
women who were susceptible to rubella (even through
multiple tests) was 4.4% (N = 20,056), while the proportion
of women who were immune was 89.7% (N = 412,431).
Included in this cohort were women with multiple tests
and differing results: 0.03% (N = 145) of all women in
this cohort were initially found to be immune and then
became susceptible to rubella, while 0.6% (N = 2,727) of
women were initially found to be susceptible and subse-
quently developed immunity. The proportion of women
whose immune status was classified as indeterminate
was 4.8% (N = 21,876), while 0.6% (N = 2,728) had some
other combination of test results.
The distribution of tests by patient age over the study
period is presented in Table 1. The highest proportion of
tests was performed among women 30–34 (31.4% or
mean annualized rate of 78.4 per 1,000) and 25–29 years
old (29.5% or mean annualized rate of 74.2 per 1,000).
In comparison, 28.1% and 33.9% of live births in Ontario
in 2009 were born to women 25–29 and 30–34 years
old, respectively (14). The proportion of prenatal tests
performed was lowest among women 15–19 years old
and women over 40 years old.
Among the 81.6% of women who had a single prenatal
test, susceptibility to rubella declined with increasing age
(Figure 4, p < 0.0001); women between 15 and 19 years of
age had the highest susceptibility to rubella (7.3%)
followed by women 20–24 years old (7.1%). Among
women who had multiple prenatal testing episodes, Table 2
presents serology results by the age of the woman at the
first test. Increased age was associated with decreased sus-
ceptibility and increased immunity (p < 0.0001 for both).
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Specifically, younger women had the highest susceptibility
(4.2% among 15–19 year-olds) and lowest immunity
(87.6% among 15–19 year olds). Notably, women were sig-
nificantly less likely to develop immunity if previously sus-
ceptible, with increasing age (p < 0.0001).
The effect of the interval between tests among women
who had multiple prenatal tests is shown in Figure 5.
Although not shown, these trends were similar across
all age groups. The proportion of women who remained
susceptible throughout repeated prenatal testing declined
as the number of years between tests increased (p < .0001).
Also, while the proportion of women who remained
immune throughout repeated prenatal testing was
unchanged at approximately 93%, the proportion of
women who were initially susceptible and then became
immune increased from 2.0% to 3.9% (p < .0001) as the
interval between the first and last tests increased.
Discussion
Our analyses showed that overall rubella susceptibility
among prenatal women in Ontario between 2006 and
2010 was 4.4% and decreased from 4.9% to 4.2% over
Labware Data Extract
(April 2010 – December 2010) 
N = 141,206 tests
Labware prenatal tests among 15-49 
year old females
N = 39,288 tests
Invalid or earlier tests 
associated with the 
same specimen
Labyrinth Data Extract
(January 2006  – April 2010) 
N = 907,723 tests
Labyrinth prenatal tests among 15-49 
year old females
N = 634,631 tests
Prenatal test results among 15-49 year old females 
N = 600,859 tests or specimens
or
N = 459,963 patients
Non-prenatal tests Non-prenatal tests
Unique valid Labyrinth test results 
N = 565,382 tests or specimens
Unique valid Labware test results
N = 35,477 tests or specimens
Invalid or earlier tests 
associated with the 
same specimen
Unique episodes of prenatal tests conducted among 15-49 year old females  
N = 551,160 tests or specimens
or
N = 459,963 patients
Tests conducted within 9 months
N=49,699 tests or specimens
Figure 1 Flowchart of data. Flowchart depicts the process by which patient-based and test-based prenatal rubella serology datasets were
derived for analysis in this study. The original number of rubella serology tests extracted from the two laboratory information systems used by
the Public Health Ontario Laboratory over the study period between 2006 and 2010 is shown (N = 1,048,929). Restricting this dataset to valid
prenatal tests conducted on women 15–49 year olds yielded 600,859 tests among 459,963 patients. Further restricting the dataset to tests
conducted at least 9 months apart resulted in a total of 551,160 test results available for analysis.
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the same time period. This is lower than the correspond-
ing level of susceptibility (4.9%) associated with the na-
tional target of 97% vaccine coverage, assuming 98%
vaccine effectiveness of one dose of rubella-containing
vaccine. However it exceeds the national target of less
than 4% susceptibility among first-time pregnant
women, particularly at the health unit level where pro-
portions as high as 9.7% were observed.
Drawing comparisons with other jurisdictions is chal-
lenging due to methodological differences, such as
2006 2007 2008 2009 2010
Susceptible 4.9 5.0 4.7 3.9 4.2
Indeterminate 5.2 5.4 5.4 4.9 7.1














Figure 2 Prenatal specimen-based rubella serology results among 15–49 year old females in Ontario, 2006–2010 (N = 551,160 tests).
This figure shows the proportion of prenatal specimens that were determined to be susceptible, indeterminate or immune to rubella among
15–49 year old females in Ontario, by year from 2006 to 2010. Immunity remained relatively stable at approximately 90% throughout the study
period. There was more variation among susceptibility, ranging between 5.0% in 2007 and 3.9% in 2009.
Toronto
Ottawa
Figure 3 Rubella susceptibility among 15–49 year old females in Ontario by health unit, 2006–2010 (N = 455,745 patients, excluding
4,218 patients for whom health unit could not be determined). The geographic distribution of Ontario women who remained susceptible to
rubella throughout the study period between 2006 and 2010 is presented in this figure. The health unit reflects the patient’s place of residence where
available, otherwise the health unit of the health care provider who submitted the request for the prenatal test is shown. The numerator includes women
who had a single test that demonstrated susceptibility, as well as women who had multiple tests that all demonstrated susceptibility. Health units were
categorised according to quartiles of susceptibility. In general, women residing in the northern health units had the highest levels of susceptibility.
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different study populations and unknown or varied
thresholds used to define immune status. Rubella sus-
ceptibility demonstrated in this analysis is lower than
what was reported in previous studies conducted among
pregnant women in Quebec (1993–1994) and Toronto,
Ontario (2002–2007), with estimates between 7.0% and
8.4% [13,15]. A study conducted in Alberta in 2002–
2005 also reported higher rubella susceptibility (8.8%)
but a higher threshold (<10 U/mL) was used to define
susceptibility [14]. The American population-based
National Health and Nutrition Examination Survey
(NHANES) estimates that 8.5% of women 20 to 49 years
of age are susceptible to rubella infection above a mod-
eled threshold of rubella elimination of greater than
87.5% population immunity [16]. The immunity demon-
strated in our study is greater than this threshold,
though it is important to note that the threshold was
not limited to prenatal women and was specific to the
United States rather than the Canadian or Ontario
population.
The significant increase in immunity with increasing
age may be attributable to increased past exposure to
natural infection, as well as more opportunities to
immunize older women during their childbearing years
either as a result of pre-conception screening or in the
post-partum period. This is further supported by the in-
creasing proportion of women who were initially suscep-
tible becoming immune over time since their first
prenatal test. Many hospitals have adopted standing or-
ders for rubella non-immune women and the benefits of
post-partum standing orders has been shown to be ef-
fective in increasing rubella immunization among non-
immune women prior to hospital discharge [17]. As
shown in Table 2 and Figure 4, higher susceptibility was
observed among adolescents and young women (15–
29 year olds). This could reflect waning immunity from
childhood vaccinations, as this cohort would have been
eligible for one dose of rubella-containing vaccine in
childhood, and antibody levels have been shown to de-
cline within a few years of vaccination [18,19]. The lack
of natural boosting due to an absence of circulating
virus, may also result in higher susceptibility particularly
among younger women [6]. Further, younger pregnant
women may access healthcare differently than older
pregnant women and thus may have different pre-
conception/prenatal health behaviours [20,21]. Although
rubella is not endemic in Canada, importation of cases
occurs, therefore these women remain at risk for rubella
infection during pregnancy which may result in congeni-
tal rubella syndrome among their offspring.
This analysis also found that younger women and
women living in northern regions of Ontario were more
likely to be susceptible to rubella. This is consistent with
a similar population-based analysis of prenatal speci-
mens conducted in Alberta where younger women and
women from northern Alberta were also significantly
Table 1 Distribution of prenatal tests among 15–49 year













15-19 27,247 4.9 12.7
20-24 84,727 15.4 38.5
25-29 162,377 29.5 74.2
30-34 172,819 31.4 78.4
35-39 85,311 15.5 36.7
40-44 17,553 3.2 6.8
45-49 1,125 0.2 0.4















Susceptible 7.3 7.1 5.5 3.8 3.5 4.0 4.7
Indeterminate 9.7 8.3 6.2 4.1 3.6 3.3 2.7














Figure 4 Rubella serology results among 15–49 year old females in Ontario who had a single prenatal test by age, 2006–2010
(N = 375,219 patients). This figure presents rubella serology results among women who had a single prenatal test between 2006 and 2010 in
Ontario, by age at the time the test was conducted. In general, susceptibility to rubella declined with increasing age; women between 15 and
19 years of age had the highest susceptibility to rubella followed by women 20–24 years old.
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more likely to have seronegative specimens [14]. Although
school-based immunization coverage data among 17-year
old students within the province reveals high vaccine
coverage (96.6%) [6], the general population may not be
representative of high risk populations such as pregnant
adolescents, and immunization status was not available for
analysis in this study. Increased susceptibility in northern
regions of Ontario could reflect barriers to immunization
due to geographic isolation and sub-optimal access to pri-
mary health care services particularly among First Nations
communities [22-24]. Health units in the northern re-
gion are more rural and tend to be more sparsely popu-
lated compared to the southern and central regions of
the province. For example, Toronto and the surround-
ing central health units comprise approximately 70% of
the provincial population, whereas just 6% of Ontarians
reside in the north.
During the 5-year study period, 81.6%, 17.1%, and
1.4% of women had one, two and three or more prenatal
tests at least nine months apart, respectively. According
to national data from Statistics Canada, 44%, 35% and
21% of all live births represented first, second and third
or higher order births [25]. This difference may be
explained by the shorter observation period used in this
study, relative to the greater number of years in which
women bear children. In our study, we observed 0.6% of
women who converted from susceptible to immune,
which may be attributed to postpartum immunization.
This is consistent with recommendations for universal
rubella screening of all pregnant women and post-
Table 2 Proportion of 15–49 year old females in Ontario who had multiple rubella serology tests, by age at first test
and selected sequence of test results, 2006–2010
Age at first test Sequence of test results
Susceptible Immune-susceptible Indeterminate Susceptible-immune Immune
15-19 years (N = 5,663) 4.2 0.3 3.1 4.9 87.6
20-24 years (N = 14,239) 3.1 0.3 2.4 4.5 89.8
25-29 years (N = 26,596) 2.0 0.2 1.6 3.7 92.5
30-34 years (N = 22,326) 1.4 0.2 1.0 2.3 95.2
35-39 years (N = 7,406) 1.8 0.1 1.0 1.8 95.3
40-49 years (N = 855) 1.3 0.4 1.6 1.1 95.5











Susceptible-Immune 2.0 3.1 3.5 3.7 3.9
Susceptible 3.0 2.3 1.8 2.1 2.3
Indeterminate 2.0 1.7 1.5 1.4 1.6
Immune-Susceptible 0.2 0.2 0.2 0.2 0.5














Figure 5 Patient-based rubella serology results among 15–49 year old females in Ontario with multiple tests by interval between first
and last test (N = 82,016 patients, excluding 2,728 patients for whom a different sequence of test results was observed). Among
women who had multiple prenatal tests between 2006 and 2010, this figure shows the distribution of women classified according to the
sequence of test results, by the number of years between the first and last test. The proportion of women who remained susceptible throughout
repeated prenatal testing declined as the number of years between tests increased; conversely, the proportion of women who were initially
susceptible and then became immune increased with longer intervals. * Interval refers to 9 months to, 1 year, as tests conducted within 9
months were considered to be associated with the same pregnancy.
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partum immunization of non-immune women [9]. What
is more concerning is the 0.03% of women who were iden-
tified as initially being immune but subsequently became
susceptible. While this may suggest waning immunity, this
may also represent women whose test results were border-
line reactive or who were incorrectly identified as the same
patient during the matching process.
There are several limitations associated with this
study. Serological results do not distinguish between
vaccine- and disease-induced immunity. However as ru-
bella is not an endemic disease in Canada and the num-
ber of cases in Ontario is low, our results likely reflect
vaccine-induced immunity. We were also limited by
specimens that were submitted to PHOL for screening.
As such, we may have missed prenatal specimens that
were submitted by private and hospital laboratories, and
our analysis was limited by the information was captured
on the requisition form. However since prenatal testing
for other diseases (i.e. hepatitis, HIV and syphilis) are
performed at PHOL and are routinely requested with ru-
bella screening, private and hospital laboratories tend to
forward rubella requisitions to PHOL. Thus, the volume
of missed tests was likely minimal. While the objectives
of this study were met, the lack of variables available for
analysis limited our ability to interpret observed trends.
For example, we were not able to determine if women
who seroconverted had received vaccination post-partum.
Future studies may consider linkages with additional data
sources. We also identified some inconsistencies in the
use of prenatal requisition forms, such as the use of these
forms among males and females outside of the 15 to
49 year age group. However as our analyses were strictly
limited to prenatal tests conducted among 15–49 year old
females, it is unlikely that non-prenatal tests were in-
cluded. Lastly, although data were compiled from two dif-
ferent laboratory information systems (Labyrinth and
Labware) during the study period, the same threshold
values were used to identify susceptible, indeterminate
and immune patients, thus eliminating inconsistencies in
the interpretation of test results.
Conclusions
Our study demonstrates that rubella susceptibility
among prenatal women in Ontario is within the range, if
not lower, than what has been reported in other jurisdic-
tions in North America, and supports elimination goals
as population immunity in this group is relatively high.
Despite this, higher susceptibility among young women
and women living in the north highlights an opportunity
for greater focus on identification and immunization of
susceptible women in these groups.
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